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Abstract
Purpose—Although metabolic syndrome incidence has substantially increased during the last 
few decades, it largely remains unclear whether this metabolic disorder is associated with total 
cancer mortality. The present study was carried out to investigate this important question.
Methods—A total of 687 cancer deaths were identified from 14,916 participants in the third 
National Health and Nutrition Examination Survey by linking them to the National Death Index 
database through December 31, 2006. Cox proportional hazards regression was performed to 
calculate hazard ratios (HR) and 95% confidence intervals (CI) for total cancer mortality in 
relation to metabolic syndrome and its individual components.
Results—After adjustment for confounders, a diagnosis of metabolic syndrome was associated 
with 33% elevated total cancer mortality. Compared with individuals without metabolic syndrome, 
those with 3, 4 and 5 abnormal components had HRs (95% CIs) of 1.28 (1.03–1.59), 1.24 (0.96–
1.60), and 1.87 (1.34–2.63), respectively (p-trend = 0.0003). Systolic blood pressure and serum 
glucose were associated with an increased risk of death from total cancer [HR (95% CI) for 
highest vs. lowest quartiles: 1.67 (1.19–2.33), p-trend = 0.002 and 1.34 (1.04–1.74), p-trend = 
0.003, respectively]. Overall null results were obtained for lung cancer mortality. The effects of 
metabolic syndrome and its components on non-lung cancer mortality were generally similar to, 
but somewhat larger than, those for total cancer mortality.
Conclusion—Our study is among the first to reveal that metabolic syndrome is associated with 
increased total cancer mortality.
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Introduction
Cancer is a leading cause of death in both developed and developing countries. It was 
reported that 14.1 million cancer cases and 8.2 million cancer deaths occurred worldwide in 
2012 [1]. On a global scale, cancers of the breast and the lung are most common in women 
and men, respectively [1]. The American Cancer Society has estimated that there were 
1,658,370 new cancer cases and 589,430 cancer deaths in the U.S. in 2015 [2]. Prostate 
cancer is the most commonly diagnosed cancer among American men, while lung cancer 
remains the leading cause of cancer death in both sexes [2]. Given the tremendous medical 
and economic burden of cancer on the world population, it is critically urgent to identify 
modifiable risk factors for its prevention and control.
Obesity is increasing at epidemic proportions in developed countries and at an alarming pace 
in developing countries [1]. It is reported that more than one billion adults are overweight 
and 315 million are obese worldwide [3]. In the U.S., more than one third (36%) of adults 
are obese [3]. Obesity is the major determinant of metabolic syndrome, an abnormal health 
condition that is well established as a precursor to type 2 diabetes mellitus and linked to the 
risk of several cancers [4–6]. Metabolic syndrome is defined as a cluster of at least three of 
the following five factors: high-density lipoprotein (HDL) cholesterol (<40 mg/dl for men 
and <50 mg/dl for women), triglycerides (>150 mg/dl), systolic blood pressure (>130 mm 
Hg), blood glucose (>100 mg/dl), and waist circumference (>102 cm for men and >88 cm 
for women) [7]. Metabolic syndrome is common in Western populations, with a prevalence 
of approximately 25% in the U.S. [8, 9].
A number of epidemiologic studies have showed that obesity is associated with an increased 
risk of colorectal, kidney, gallbladder, endometrial, prostate, and post-menopausal breast 
cancer [10, 11]. Some studies also revealed that obesity increased all-cause and total cancer 
mortality [12–16]. However, epidemiological data on the association between metabolic 
syndrome and cancer have been relatively scarce and inconsistent. In some studies, 
metabolic syndrome was found to modulate total cancer mortality in men [17, 18] but not in 
women [18]. Some other studies have evaluated the influence of individual metabolic 
syndrome components on cancer mortality, with mixed results [19–22]. Although 
investigating metabolic syndrome and its individual components in relation to cancer risk 
may shed light on the biological mechanisms by which obesity alters carcinogenesis [17], no 
epidemiologic studies have systematically examined this research question in a national 
representative sample of the general U.S. population. Therefore, the present study sought to 
evaluate whether metabolic syndrome and its individual components are associated with 
total cancer mortality in the Third National Health and Nutrition Examination Survey 
(NHANES III).
Materials and Methods
Study subjects
Data collected from the NHANES III (1988–1994) were analyzed in the present study. 
NHANES III was conducted by the U.S. National Center for Health Statistics (NCHS) of the 
Centers for Disease Control and Prevention (CDC). The survey design and methodology of 
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the NHANES III have been described in detail elsewhere [23]. Death from cancer for each 
of the participants was ascertained by a probabilistic match between NHANES III database 
and the death certificate records of the U.S. National Death Index [23]. The follow-up period 
for each subject was calculated as the time from the date of health examination to the 
occurrence of cancer death or the censor date (December 31, 2006), whichever occurred 
first. Total cancer mortality included deaths from all sites of cancer defined by the 9th 
revision of the International Classification of Diseases (ICD).
Data on the individual components of metabolic syndrome were available from 19,618 
participants aged 18 years or older. A total of 322 pregnant women were excluded because 
of increased waist circumference and potential metabolic changes following pregnancy. 
Given the objective of the present study, participants who died from a cancer diagnosed at 
baseline (i.e. date of health examination) (n=190) also were excluded from analysis. These 
exclusions led to 19,106 participants in the cohort. A total of 946 cases of cancer deaths 
were documented from the 19,106 participants during a follow-up of 250,443 person-years. 
The anatomic sites of cancer for the 946 cases included cancers of the lung (n = 279), colon 
and rectum (n = 93), prostate (n = 70), breast (n = 56), pancreas (n = 46), and other organs (n 
= 402). Of the 19,106 participants, 14,916 had data on all five components of metabolic 
syndrome and gave rise to 687 cases of cancer death (including 201 cases of lung cancer). 
The numbers of participants with missing data for individual components are 2,992 for waist 
circumference, 2,704 for triglycerides, 2,783 for HDL cholesterol, 2,168 for systolic blood 
pressure, and 2,907 for blood glucose.
In the NHANES III, subjects were recruited from the civilian, noninstitutionalized U.S. 
population using a stratified, multistage probability sampling strategy, and those who had a 
low income, were older (≥60 years of age), or were members of minority groups (African or 
Mexican Americans) were oversampled. The NCHS Institutional Review Board approved 
the survey protocols, and informed consent was obtained from all subjects. The present 
study was not reviewed by the Institutional Review Board of Indiana University as the data 
analyzed are de-identified and publicly accessible.
Data Collection
Data analyzed in this paper were collected using standardized household interviews and 
health examinations [24]. A home interview was conducted and then followed by an 
extensive physical examination and blood collection at a mobile examination center. Self-
reported information, including demographic, socioeconomic, and anthropometric 
characteristics as well as medical conditions and medications, were gathered using validated 
questionnaires during the home interview [24]. Metabolic syndrome was diagnosed 
according to the criteria of the National Cholesterol Education Program, which have been 
described in the Introduction of this paper. The individual components of metabolic 
syndrome [i.e. waist circumference, blood pressure, serum triglycerides, serum HDL 
cholesterol, and serum glucose] were measured using standard protocols or well-established 
methods during the physical examination. Specifically, waist circumference was determined 
at the iliac crest after a normal exhalation of breath. Systolic blood pressure (mmHg) was 
measured using a mercury sphygmomanometer while subjects were in a seated position. 
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Three measurements were taken and averaged for each subject to minimize measurement 
error [24]. Fasting blood samples were drawn by trained phlebotomists and were kept in 
freezers until time of analysis [24]. Serum concentrations of triglycerides and HDL 
cholesterol were measured enzymatically with Hitachi 704 Analyzer, while serum levels of 
glucose was determined using the glucose hexokinase method with Hitachi 737 Analyzer 
[24].
Statistical Analysis
Means (standard deviations) and percentages were calculated to show differences in the 
characteristics of study subjects by the number of abnormal metabolic syndrome 
components. Cox proportional hazards regression was used to estimate the hazard ratios 
(HR) and 95% confidence intervals (CI) for total cancer mortality, lung cancer mortality, and 
non-lung cancer mortality in relation to presence of metabolic syndrome, each of its 
individual components, and a composite score. Anatomic site-specific analysis was carried 
out only for lung cancer due to its relatively large sample size (n=201). Each of the 
individual components was examined by both dividing all subjects into quartiles and using 
its cut-off point specified in the Introduction section. HRs and 95% CIs were calculated with 
subjects who were in the lowest quartile (or whose value is less than the cut-off point) as the 
reference group, except HDL cholesterol for which the reference group were those who were 
in the highest quartile (or whose value is more than or equal to the cut-off point). The 
composite score has a range of 0–5, with 0 indicating no abnormal metabolic syndrome 
components and 1–5 representing the presence of 1–5 abnormal components, respectively. 
Based on the diagnosis criteria of metabolic syndrome, subjects with the composite score of 
3, 4, or 5 were classified as having this metabolic disorder.
Selecting potential confounders was largely based on their relevance to metabolic syndrome 
and cancer risk [9]. The variables were adjusted as confounders in the regression models if 
they altered parameter estimates by ≥10% and/or had a p-value (<0.25) for their regression 
coefficients [25]. The multivariable models were adjusted for age (years), gender, race (non-
Hispanic White, non-Hispanic Black, Mexican American, and other race), education (no 
education, less than high school, high school, college and graduate education), cigarette 
smoking (never, former, and current), alcohol intake (never, 1–2 drinks/day, 3–4 drinks/day 
or >4 drinks per day), and use of insulin (or diabetes), hypertension, and cholesterol-
lowering medications (yes or no for each of the medications). Potential interactions of 
gender with each of individual metabolic syndrome components and its composite score 
were evaluated because gender differences in metabolic syndrome have been reported 
previously [26]. As none of the interactions tested was statistically significant, data analysis 
was not stratified by gender. Tests for linear trend across the quartiles of each component of 
metabolic syndrome or the four categories of its composite score were performed by 
including in the models an ordinal variable representing the median value of each quartile or 
category. A weight statement with a weight variable (WTPFEX6) was included in all 
analytical procedures to account for complex survey design, survey non-response, and post-
stratification [27]. As the present study focused on metabolic syndrome, all of our data 
analysis was confined to the 14,916 subjects with complete data on this metabolic disorder. 
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All statistical analyses were conducted using SAS (version 9.3). All tests were two-sided 
and a p-value of <0.05 was considered statistically significant.
Results
The characteristics of study subjects are summarized in Table 1. Metabolic syndrome was 
present among 4,448 (29.8%) of 14,916 subjects. Subjects who were diagnosed with 
metabolic syndrome were more likely to be older, Mexican-American, and less educated. As 
expected, waist circumference, systolic blood pressure, and serum concentrations of 
triglycerides and glucose increased but serum concentrations of HDL cholesterol decreased 
with an increasing number of abnormal metabolic syndrome components.
Risk estimates described below are for subjects of all ages and both sexes. Results of total 
cancer mortality, lung cancer mortality, and non-lung cancer mortality in relation to 
metabolic syndrome as a single entity and the number of its individual components are 
displayed in Table 2. Individuals who developed metabolic syndrome had a 33% elevated 
total cancer mortality compared to those who were free from this abnormal health condition 
(HR, 1.33; 95% CI: 1.11–1.59). Of note, the risk of death from total cancer increased with 
an increasing number of abnormal metabolic syndrome components (p for trend = 0.0003). 
Specifically, compared with subjects who had 0–2 abnormal components, those who had 3, 
4, and 5 abnormal components exhibited a 28%, 24%, and 87% increased risk of death from 
total cancer, respectively.
Results of individual metabolic syndrome components in relation to total cancer mortality, 
lung cancer mortality, and non-lung cancer mortality are shown in Table 3. After adjustment 
for confounders, systolic blood pressure and serum glucose were associated with an 
increased risk of death from total cancer [HR (95% CI) for highest vs. lowest quartiles: 1.67 
(1.19–2.33), p-trend =0.002 and 1.34 (1.04–1.74), p-trend = 0.003, respectively]. There was 
a positive but borderline significant association between waist circumference and total 
cancer mortality [HR (95% CI) for highest vs. lowest quartiles: 1.32 (0.98–1.77), p-trend = 
0.05]. Overall, serum triglycerides was positively and serum HDL cholesterol was inversely 
associated with total cancer mortality, but these associations did not have significant trends 
across quartiles. When these components were analyzed as dichotomous variables based on 
their respective cut-off points for defining metabolic syndrome, waist circumference, 
systolic blood pressure, HDL cholesterol, and serum glucose were associated with an 
increased risk of death from total cancer (Table 4).
Tables 2, 3, and 4 show no significant associations of metabolic syndrome and its individual 
components (except systolic blood pressure) with lung cancer mortality. The results for non-
lung cancer mortality are largely similar to those for total cancer mortality, but the effects of 
metabolic syndrome and its components generally are somewhat larger on the former than 
on the latter (Tables 2 and 4). There is a monotonic upward trend for the association between 
number of abnormal components and non-lung cancer mortality [HR (95% CI) for 0–2 
(reference) vs. 3, 4, and 5 components: 1.30 (0.98–1.73), 1.36 (0.98–1.88), and 2.68 (1.80–
3.98), p-trend <.0001] (Table 2).
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Discussion
The present study found statistically significant associations of all five individual metabolic 
syndrome components with total cancer mortality. The presence of metabolic syndrome as a 
whole is associated with a 33% elevated risk of death from total cancer. Furthermore, this 
promoting effect on total cancer mortality increased with an increasing number of abnormal 
metabolic syndrome components.
A number of epidemiologic studies have investigated the associations of metabolic 
syndrome and its components with the risk of developing cancer [10, 11]. Specifically, 
metabolic syndrome and its components have been associated with an increased mortality 
from cancers of the prostate [28, 29], breast [30–32], bone marrow (leukemia) [33], pancreas 
[33, 34], colon [35, 36], liver [34], and other sites of the digestive system [37]. It is well 
recognized that most cancer deaths occur among patients diagnosed with aggressive, 
advanced or metastatic cancer, a clinically important phenotype in contrast to a less 
impactful form of indolent, localized cancer. Therefore, evaluating risk factors in relation to 
cancer mortality is more relevant to the elucidation of the etiology of biologically aggressive 
cancer as numerous cases of cancer with little or no potential to progress to clinical 
significant stage have been diagnosed following screening tests (e.g. prostate and breast 
cancer) [38]. However, relatively few epidemiologic studies have evaluated the influence of 
metabolic syndrome and its components on the mortality of total cancer and site-specific 
cancers. The present study revealed that metabolic syndrome was associated with an 
increased risk of death from total cancer among a representative sample of the U.S. 
population, which is consistent with the results of a Korean cohort study (RR, 1.41; 95% CI, 
1.08–1.84) carried out among 42,336 men and 32,168 women [18].
Besides analysis of metabolic syndrome as a single entity, examining its individual 
components and their combinations may shed new light on the role of this metabolic 
disorder in carcinogenesis. In the present study, we found that subjects who were in the 
highest quartile of systolic blood pressure and serum glucose experienced a significantly 
higher risk of total cancer mortality than those in the respective lowest quartiles (all p values 
for trend were <0.05). These results were in agreement with those of most previous studies 
[18, 20, 22, 39–41]. We also observed increased total cancer mortality in subjects with high 
serum triglycerides or low HDL cholesterol. However, risk estimates were statistically 
significant only for subjects who were in the third quartile of triglycerides or HDL 
cholesterol (p for trend for each of them was >0.05). In addition, given inconsistent 
associations between blood lipids and cancer risk across epidemiologic studies [42] and lack 
of the dose-response relations, chance findings for serum triglycerides and HDL cholesterol 
could not be entirely ruled out. Of note, the aforementioned results of metabolic syndrome 
components that were evaluated in quartiles were largely confirmed by the analysis that used 
their respective cut-off points for defining this adverse health condition. It is worth 
emphasizing that the present study revealed that the risk of total cancer mortality and 
particularly non-lung cancer mortality increased with an increasing number of metabolic 
syndrome components in a dose-response manner, suggesting a synergistic effect of these 
individual risk factors. This strategy of data analysis was not employed in most previous 
studies on metabolic syndrome.
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There are some potential biological mechanisms by which metabolic syndrome modulates 
cancer risk. Metabolic syndrome prevalence has been rising as a consequence of upward 
trends in prevalence of overweight and obesity during the last few decades worldwide. 
Obesity (particularly central and visceral obesity) has been associated with insulin resistance 
and elevated insulin-like growth factor 1 (IGF-1) [43, 44]. Adipose tissue is an important 
source of estrogen in postmenopausal women among whom most cases of breast cancer 
occur [45]. Circulating estrogen concentrations are elevated among overweight and obese 
individuals probably because obesity-related inflammation induces the expression of 
cyclooxygenase-2 that consequently leads to enhanced aromatase expression and estrogen 
synthesis [44, 46, 47]. Considering that insulin, IGF-1, and estrogen have been identified as 
risk factors for breast and other common cancers [48, 49], it is thereby reasonable to infer 
that obesity promotes carcinogenesis at least in part through obesity-initiated metabolic 
syndrome.
Metabolic syndrome may also alter cancer risk through its critical role in type 2 diabetes 
mellitus and chronic systematic information induced by obesity. Obesity is an established 
risk factor for both diabetes and some sites of cancer [50]. Substantial evidence indicates 
that metabolic syndrome is a strong predictor of diabetes [51]. Furthermore, most 
epidemiologic studies conducted in diverse populations have shown that diabetes is 
associated with an increased risk of the cancers of the endometrium, pancreas, liver, colon, 
rectum, breast, and urinary bladder [50, 51], although reverse causality could account in part 
for the association between diabetes and pancreatic cancer risk [50]. Obesity has been 
consistently linked to chronic inflammation, which leads to changes in the tissue 
microenvironment that facilitate cancer initiation, progression, and metastasis [52]. In 
obesity, pro-inflammatory cytokines, such as interleukin (IL)-6, IL-1β, and tumor necrosis 
factor (TNF)-α, are released from macrophages resident in adipose tissue, and these 
inflammatory mediators stimulate tumor growth and inhibit DNA repair mechanisms [51, 
52].
The strengths of the present study include that the effect of metabolic syndrome on total 
cancer mortality was investigated in a prospective cohort study that was based on a national 
representative sample of the U.S. population. All five anthropometric, physiological, or 
biochemical components of metabolic syndrome were objectively measured with validated 
assessment tools or experimental methods. Therefore the data collected for these exposures 
are free from recall bias, which is frequently present in questionnaire-based exposure 
assessment. All potential confounders were tested and adjusted as appropriate for the 
associations of interest. More importantly, metabolic syndrome as a whole, its individual 
components, and their combinations were evaluated in relation to the risk of total cancer 
mortality, lung cancer mortality and non-lung cancer mortality in our data analysis.
Some limitations exist in the present study. The components of metabolic syndrome were 
measured only once, and therefore the effect of changes in these risk factors over time on 
total cancer risk could not be evaluated. Measurement errors for the five metabolic syndrome 
components, if non-differential, are likely to lead to attenuated risk estimate of their 
associations with cancer mortality. As in other observational studies, it is possible that 
residual confounding due to unmeasured or inaccurately measured confounders might have 
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somewhat distorted the results obtained from the present study. Metabolic syndrome and its 
components in relation to site-specific cancers were not examined due to small sample size 
(described in Materials and Methods). Of all sites of cancer, lung cancer contributed to the 
largest number of deaths (n=201) in the present study. We examined metabolic syndrome 
and its components in relation to lung cancer mortality but did not identify overall apparent 
effects. It is intriguing to observe that the dose-response relation with the number of the 
abnormal components of metabolic syndrome is more pronounced and statistically 
significant for non-lung cancer mortality than for total cancer mortality, which may be in 
part ascribed to its overall null results with lung cancer mortality.
In summary, metabolic syndrome and its individual components are associated with an 
increased risk of total cancer mortality and non-lung cancer mortality. The findings of the 
present study offer novel evidence for the potential role of metabolic syndrome in 
carcinogenesis and mechanistic data for the associations between obesity and cancer risk. If 
the results of this study are confirmed in other well-conducted case-control and particularly 
prospective cohort studies, the public health importance of maintaining healthy levels of the 
components of the metabolic syndrome would be accentuated. This strategy is expected to 
result in a tremendous reduction in cancer incidence and mortality attributable to the global 
epidemic of obesity and subsequent metabolic syndrome.
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Table 1
Baseline characteristics of 14,916 participants by the number of abnormal metabolic syndrome components in 
the Third National Health and Nutrition Examination Survey, 1988–1994
Characteristics
No. of abnormal metabolic syndrome components
0–2 (n=10,468) 3 (n=2,452) 4 (n=1,460) 5 (n=536)
Mean (SD)
Age (year) 39.7 (18) 50.4 (18) 56.2 (16) 61.6 (13)
Waist circumference (cm) 87.0 (13) 102.1(12) 107.7(12) 109.3 (11)
Systolic blood pressure (mmHg) 117.2 (17) 131.0 (20) 137.3 (19) 146.1 (15)
Serum triglycerides (mg/dl) 108.8 (66) 204 (132) 246.0 (130) 289 (155)
Serum HDL cholesterol (mg/dl) 53.5 (15) 43.5 (13) 39.7 (11) 36.6 (7)
Serum glucose (mg/dl) 90.4 (21) 104 (44) 117 (55) 151.4 (71)
N (%)a
Sex
 Male 5122 (74.5) 1151 (14.5) 669 (8.6) 204 (2.3)
 Female 5346 (75.3) 1301 (14.0) 791 (7.7) 332 (3.0)
Race
 Non-Hispanic White 4107 (74.0) 1055 (14.5) 706 (8.5) 282 (3.0)
 Non-Hispanic Black 3086 (78.5) 585 (13.4) 284 (6.4) 85 (1.8)
 Mexican-American 2822 (73.5) 722 (16.0) 419 (8.1) 157 (2.5)
 Other race 453 (79.6) 90 (12.1) 51 (7.0) 12 (1.2)
Educationb
 Never been to school 192 (65.6) 86 (16.8) 74 (11.4) 32 (6.2)
 Less than High school 1819 (61.3) 610 (19.6) 417 (14.4) 169 (4.7)
 High school education 5133 (73.0) 1160 (14.8) 667 (9.1) 244 (3.2)
 College education 2645 (80.6) 477 (12.4) 236 (5.3) 73 (1.7)
 Graduate education 613 (80.6) 108 (11.7) 62 (6.3) 17 (1.4)
Cigarette Smoking
 Never 5398 (71.9) 1136 (15.1) 706 (9.4) 265 (3.5)
 Former 2884 (75.3) 597 (15.6) 269 (7.0) 78 (2.0)
 Current 2186 (61.0) 719 (20.1) 485 (13.5) 193 (5.4)
Alcohol Consumptionc
 No alcohol 4870 (67.9) 1458 (17.1) 945 (11.0) 378 (4.0)
 1–2 drinks/day 5295 (80.1) 942 (12.2) 494 (6.0) 149 1.7)
 3–4 drinks/day 235 (84.6) 38 (9.5) 15 (4.5) 4 (1.4)
 >4 drinks/day 68 (86.9) 14 (6.7) 6 (2.9) 5 (3.4)
a
Percentages were calculated by using sample weights to report estimates that would be representative of the U.S. population.
b
Eighty-two participants had missing data on education.
c
In the NHANES, one drink was defined as 10 gram pure ethanol that is equivalent to 12 ounces of beer, 4 ounces of wine or 1 ounce of hard liquor 
[53].
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